Theratechnologies Inc, a leading pharmaceutical company, represents a core set of values and corporate philosophy. With a strong commitment to innovation and patient-centricity, Theratechnologies focuses on developing groundbreaking therapies to address unmet medical needs. The company's corporate philosophy revolves around fostering a culture of integrity, collaboration, and social responsibility. By prioritizing scientific excellence, Theratechnologies demonstrates its dedication to improving the lives of patients worldwide. With its unwavering dedication to research and development, Theratechnologies continues to shape the future of healthcare by delivering innovative treatments and providing hope for patients and their families.

Theratechnologies Inc is primarily present in Canada and the United States.

Theratechnologies Inc has achieved significant milestones in its journey. The company successfully developed and gained regulatory approval for its innovative HIV treatment, EGRIFTA®. This medication helps manage excess abdominal fat in HIV-infected patients. Theratechnologies Inc also expanded its global presence by securing marketing authorizations in multiple countries. The company further strengthened its product portfolio by launching Trogarzo®, a breakthrough treatment for multidrug-resistant HIV-1. Additionally, Theratechnologies Inc has established strategic partnerships with renowned organizations, enabling greater market reach and research collaborations. These milestones exemplify the company's commitment to advancing the field of HIV therapeutics and improving patient outcomes.

Theratechnologies Inc is a Canadian pharmaceutical company specializing in the development and commercialization of innovative therapies. Founded in 1993, Theratechnologies has continuously focused on discovering treatments for unmet medical needs. The company has made significant advancements in the field of HIV-associated lipodystrophy, with its flagship product Egrifta being approved by regulatory authorities in the United States, Europe, and Canada. Theratechnologies is committed to delivering effective therapies that improve patients' quality of life. With a strong dedication to research and development, the company has established itself as a key player in the pharmaceutical industry.

The main competitors of Theratechnologies Inc in the market include companies such as Gilead Sciences, Inc., AbbVie Inc., and Novartis AG.

Theratechnologies Inc is primarily active in the pharmaceutical industry.

The business model of Theratechnologies Inc. is focused on developing and commercializing innovative therapies for people living with serious medical conditions. Theratechnologies specializes in targeted peptide-based therapies and has expertise in developing products for the treatment of HIV-associated lipodystrophy and human growth hormone deficiency. The company strives to address unmet medical needs through research, development, and commercialization of safe and effective therapies. Theratechnologies aims to improve the quality of life for patients by bringing innovative treatments to market and collaborating with healthcare professionals.

Theratechnologies KGV ir -195,64.

Theratechnologies KUV ir 0,40.

AlleAktien kvalitātes vērtējums Theratechnologies ir 5/10.

gaidāmā Theratechnologies apgrozījums ir 90,52 milj. USD.

gaidāmā Theratechnologies peļņa ir -186 957,34 USD.

Theratechnologies Inc. is a biopharma company based in Montreal, Canada, specializing in the research, development, manufacturing, and marketing of medications for the treatment of immune system and metabolic diseases. The company is divided into three business segments: therapeutics, diagnostics, and partner programs. The therapeutics division focuses on the development, manufacturing, and marketing of medications used in chronic immune system and metabolic diseases, such as HIV infections, obesity, and diabetes. Therapeutic products from Theratechnologies aim to improve healthcare by enhancing the quality of life for patients with chronic illnesses. Theratechnologies has also gained expertise in the biotherapeutic development and manufacturing of antibodies and is working on the development of antibodies for the treatment of autoimmune diseases. The diagnostics business of Theratechnologies is dedicated to the production of diagnostic tests for the detection of HIV infections. These tests have played a crucial role in monitoring therapy for HIV patients and the treatment of HIV infections. Theratechnologies is also involved in the development of partner programs aimed at expanding the company's product range. These programs involve innovative product development, collaborations, and licensing agreements with other companies and institutions. Theratechnologies has a number of significant product developments and patents that support the growth of the company. Some of the key products of the company include: - EGRIFTA®: This medication is used for the treatment of excess fat tissue in HIV patients. EGRIFTA® stimulates hormone production and reduces fat tissue. - Trogarzo®: Trogarzo® is an anti-HIV medication used in patients who are resistant to other HIV medications. This medication prevents the binding of HIV to the T-cell receptor and the entry of the virus into the cell. - TH1902: This medication is a combination of a cytotoxic agent and a carrier protein. TH1902 targets cancer cells by selectively delivering the cytotoxic agent to the tumor. Theratechnologies has become a key player in the biopharma industry by continuously investing in research and development of new products and forming partnerships with other industry leaders. This business model has facilitated the company's growth in recent years and provides a solid foundation for a promising future.

Theratechnologies izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Theratechnologies vai uzņēmums nedod dividendes.

Theratechnologies ISIN ir CA88338H1001.

Theratechnologies WKN ir 915439.

Theratechnologies simbols ir TH.TO.

Pēdējo 12 mēnešu laikā Theratechnologies maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Theratechnologies plāno maksāt dividendes 0 USD apmērā.

Theratechnologies pašreizējā dividendu rentabilitāte ir .

Theratechnologies maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Theratechnologies pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Theratechnologies tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Theratechnologies apmērā 0 USD, kas tika izmaksāta 4.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 4.07.2024..

Pēdējās dividendes izmaksa notika 4.07.2024..

Gadā 2023, Theratechnologies izmaksāja 0 USD dividendes.

Theratechnologies dividendes tiek izmaksātas USD.